Price T Rowe Associates Inc. MD Has $148.75 Million Position in Encompass Health Co. (NYSE:EHC)

Price T Rowe Associates Inc. MD lifted its stake in Encompass Health Co. (NYSE:EHC - Free Report) by 22.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,610,669 shares of the company's stock after acquiring an additional 300,386 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 1.60% of Encompass Health worth $148,746,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Encompass Health by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 10,404,081 shares of the company's stock worth $960,817,000 after acquiring an additional 138,196 shares during the last quarter. Invesco Ltd. increased its stake in shares of Encompass Health by 3.3% in the fourth quarter. Invesco Ltd. now owns 5,536,251 shares of the company's stock worth $511,273,000 after acquiring an additional 176,135 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Encompass Health by 6.0% in the fourth quarter. Alliancebernstein L.P. now owns 2,076,869 shares of the company's stock worth $191,799,000 after purchasing an additional 117,617 shares in the last quarter. FMR LLC boosted its holdings in Encompass Health by 0.8% in the fourth quarter. FMR LLC now owns 1,973,846 shares of the company's stock worth $182,285,000 after purchasing an additional 15,831 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Encompass Health by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,679,774 shares of the company's stock worth $155,176,000 after purchasing an additional 6,164 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Stock Performance

Shares of NYSE EHC traded down $1.01 during mid-day trading on Thursday, hitting $115.98. The company had a trading volume of 949,953 shares, compared to its average volume of 683,156. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. The business's 50-day simple moving average is $101.07 and its 200-day simple moving average is $98.96. Encompass Health Co. has a 12 month low of $82.38 and a 12 month high of $117.52. The firm has a market cap of $11.68 billion, a P/E ratio of 26.00, a PEG ratio of 2.31 and a beta of 0.87.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, beating analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same period in the previous year, the business earned $1.12 earnings per share. The company's quarterly revenue was up 10.6% on a year-over-year basis. As a group, analysts predict that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.59%. Encompass Health's dividend payout ratio (DPR) is 14.05%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on EHC shares. Royal Bank of Canada upped their price objective on shares of Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a report on Monday. William Blair reiterated an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. KeyCorp upped their price target on shares of Encompass Health from $120.00 to $122.00 and gave the company an "overweight" rating in a report on Friday, April 25th. UBS Group upped their price target on shares of Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday. Finally, Truist Financial restated a "buy" rating and set a $135.00 price target (up from $116.00) on shares of Encompass Health in a report on Monday. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $120.86.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, EVP John Patrick Darby sold 10,000 shares of the company's stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total value of $1,147,900.00. Following the sale, the executive vice president now directly owns 79,710 shares in the company, valued at $9,149,910.90. This represents a 11.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Andrew L. Price sold 5,042 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at approximately $6,798,129.56. This represents a 6.79 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.10% of the company's stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.